Physician profile
Gregory G Smith
NPI 1952322596
$15,818.42
in general payments reported to CMS, 2019-2025
47 companies · $3,183 in 2025
The $3,183 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,337 · 2020: $1,090 · 2021: $1,683 · 2022: $2,470 · 2023: $2,331 · 2024: $2,726 · 2025: $3,183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,239.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,499.01 | 2019-2024 | Rybelsus, Ozempic |
| Neurocrine Biosciences, INC. | $1,429.75 | 2022-2025 | Ingrezza |
| Astrazeneca Pharmaceuticals LP | $1,364.78 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,241.08 | 2019-2024 | Jardiance |
| Lilly USA, LLC | $974.36 | 2019-2025 | Amyvid, Emgality, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $931.38 | 2021-2025 | |
| Ucb, INC. | $704.18 | 2019-2025 | Fintepla |
| Merck Sharp & Dohme LLC | $540.94 | 2019-2023 | Verquvo |
| Regeneron Healthcare Solutions, INC. | $470.30 | 2022-2025 | Dupixent |
| Otsuka America Pharmaceutical, INC. | $441.05 | 2023-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Biohaven Pharmaceuticals, INC. | $419.96 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $349.21 | 2024-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Novartis Pharmaceuticals Corporation | $343.60 | 2019-2023 | |
| Glaxosmithkline, LLC. | $333.68 | 2019-2024 | Arexvy, Nucala |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $316.32 | 2021-2025 | Caplyta |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.